Trials / Completed
CompletedNCT02508506
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 5461 | Single dose, given orally |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-07-27
- Last updated
- 2016-02-04
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02508506. Inclusion in this directory is not an endorsement.